Sun Pharma is officially experiencing its moment of glory. The Indian giant has shed its label as a “low-cost provider” to strategically pivot towards high-value specialty products. Despite some regulatory obstacles and sustained R&D expenses, the strategy is clearly paying off.
“The world’s pharmacy” showed impressive strength in 2025. The Indian pharmaceutical industry reached a record revenue of INR 4,720 billion, or approximately $50.5 billion.
For the first time ever, exports rose to $30.47 billion, up 9.4% from the previous year’s $27.85 billion, according to the Indian Ministry of Commerce and Industry. The United States remains the main customer, absorbing nearly $9 billion in exports, constituting a massive market share of 14.29%.
As the global market is expected to grow from $1.6 trillion to $2.3 trillion by 2030 according to a Grand View Research report, India is quickly moving beyond its role as a provider of cheap generics.
Leading the pack is Sun Pharmaceutical Industries Ltd, a national titan that has reinvented itself. The company spent the year transforming into a global leader in specialty products, setting the pace for the future of healthcare in India. This shift resulted in double-digit profit growth for the financial year.
Context: Sun Pharma has received international recognition for its strategic shift towards high-value specialty products, which has led to significant financial success.
Fact Check: The Indian pharmaceutical industry reached a record revenue of INR 4,720 billion in 2025.
Sun Pharma reported a total revenue of INR 520.4 billion, a 9% increase from the previous year. The net profit was even more impressive, with an adjusted net profit of INR 119.8 billion, a 19% year-on-year increase. This growth was driven by the Global Specialty division, which emerged as a major growth driver.
The domestic Indian market remained dominant, accounting for 33% of the total activity. Sales there reached INR 169.2 billion, up 13.7% from the previous year. Activity in the United States contributed 31% to the mix, with sales of INR 162.4 billion, showing a consistent 3.6% year-on-year growth.
“Ilumya,” the company’s drug used to treat moderate to severe plaque psoriasis in adults, generated $681 million in global sales for the 2025 fiscal year. Additionally, the active pharmaceutical ingredients (API) segment and other revenues increased by 11% year-on-year to reach INR 21.29 billion.
Context: Sun Pharma’s financial performance was driven by strong sales growth in its specialty products and active pharmaceutical ingredient segments.
Fact Check: Sun Pharma invested INR 32.48 billion in its R&D labs during the 2025 fiscal year, with a significant portion allocated to the Global Specialty division and innovation pipeline.
Approximately 40% of the total R&D budget was dedicated to generic filings and 14 new drug applications pending approval from the US FDA. Despite this substantial investment in future innovation, the company’s recent stock performance has slightly decreased compared to its historical peaks.
Context: Sun Pharma’s emphasis on R&D investment showcases its commitment to advancing in the pharmaceutical space.
Fact Check: Sun Pharma’s stock price showed a slight decline over the last 12 months, but analysts predict a potential upside of 18-44% based on various factors.
Context: Analysts remain optimistic about Sun Pharma’s future potential, with a majority recommending a buy rating on the stock.
Fact Check: Sun Pharma faces challenges from US tariff increases and potential acquisitions, which could impact its conservative management reputation.
Adding to this, persistent challenges in complying with USFDA regulations in manufacturing facilities could lead to a tumultuous journey ahead.
